Browsing: Pretreated

The treatment landscape for pancreatic cancer has long been characterized by limited therapeutic options and a survival rate that has…

The phase 3 RASolute 302 trial (NCT06625320) evaluating the multi-selective RAS(ON) inhibitor daraxonrasib has met its primary and key secondary…

Patients treated with the investigational allogeneic anti-CD19 CAR T-cell therapy cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL) who tested…

Developers from Nuvalent have submitted a new drug application (NDA) for neladalkib, an investigational ALK-selective inhibitor, as a therapy for…

In a Between the Lines program following the 2026 ASCO Genitourinary Cancers Symposium, experts convened to discuss findings from the…

Namodenoson (CF102) successfully met its primary end point of safety and tolerability in a phase 2a trial (NCT06387342) of patients…

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of pembrolizumab (Keytruda) in…

In a conversation with CancerNetwork®, Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed preliminary efficacy and safety data from a…